Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

New This Week On Slingshot Insights SA Premium Service: 9/4/18

|About: Kadmon Holdings (KDMN), TGTX, XENE
Summary

This week's Marketplace postings include interviews with experts discussing assets from: XENE, KDMN, TGTX.

This series of instablog posts will highlight the most recently executed transcripts being added to the “Become the Smart Money” , Slingshot Insights Seeking Alpha Premium service. In these blog posts we will give you a bit more information about the subject matter experts we interviewed, the topics covered, and relevant companies. We hope that these brief overviews, combined with our free content and articles, will display what we believe is the content’s unique value to our members. Please don’t hesitate to directly ask us questions at any time via SeekingAlpha Direct message or email to info@slingshotinsights.com.

Why Do Expert Research?

While many individuals we speak to are unaware of the role expert interviews play for many professional investors, it is a $600mm industry. Many funds pay in excess of $100,000 a year just for a relationship with an expert network and over a thousand dollars per call. While these numbers sound staggering, many investors consider them well worth the money. Slingshot Insights’ sharing model has transformed the price of these calls for our customers and now we are making them even more affordable to you on the SeekingAlpha Marketplace for only $75 per month.

Become the newest subscriber to “Become the Smart Money” here and gain access to all of these : Link

Transcript 1: Digging into Xenon's epilepsy pipeline including XEN1101 and XEN901

Ticker: XENE

Call Date: 8/01/2018

Who's the Expert?

  • Director of Epilepsy and Clinical Neurophysiology at Boston Children's & Professor of Neurology at Harvard
  • Currently manages ~500 patients with epilepsy.
  • Research focuses on metabolic causes of childhood epilepsies; member of the FDA Neurothapeutics Advisory Committee.

Interview Goal:

To better a better understanding of two therapies currently in development by Xenon (XENE) to treat epilepsy, XEN1101 (Kv7 Potassium Channel Opener) and XEN901 (Nav1.6 Sodium Channel Inhibitor).

Link to original project page on Slingshot Insights with questions asked: link

Transcript 2: A 2nd Look: Investigating Kadmon's ROCK Inhibitor Platform in Fibrosis, specifically KD025 in IPF

Ticker: KDMN

Call Date: 8/01/2018

Who's the Expert?

  • Professor and Chair, Department of Medicine, & Vera and Paul Guerin Family Distinguished Chair in Pulmonary Medicine at Cedars-Sinai.
  • Physician scientist with an active research laboratory focused on elucidating the basic mechanisms of lung fibrosis.
  • Research laboratory has been funded by the National Institutes of Health for the past twenty years; involved in industry-sponsored clinical trials evaluating new therapies in IPF and participated in both the pirfenidone and nintedanib programs that led to the first FDA approved treatments for IPF.

Interview Goal:

To get a better understanding of the mechanistic and pathway rationale of oral Rho-associated coiled-coil kinase 2 "Rock2" inhibition in Fibrosis. The conversation will also focus on the public data for KD025 in IPF.

Link to original project page on Slingshot Insights with questions asked: link

Transcript 3: A discussion on TG Therapeutics' Umbralisib and the potential of Pi3K pathway in treating CLL

Ticker: TGTX

Call Date: 8/03/2018

Who's the Expert?

  • Clinical Director, Adult Lymphoma Program at Dana Farber, Assistant Professor of Medicine, Harvard Medical School & Director, Histiocyte Disorders Center.
  • Currently manages 100 patients with CLL, 50 with CTCL & 30 patients with RR LDBCL.
  • Research focuses on CAR T-cell therapy, Lymphoma, and Stem cell/bone marrow transplantation.

Interview Goal:

This call with focus on the UNITY-CLL trial in both front line and relapse/refractory CLL

Link to original project page on Slingshot Insights with questions asked: link

Become the newest subscriber to “Become the Smart Money” here and gain access to all of these interview and more : Link

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.